Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Jo Vanrutten
Aug 10, 2023 3:10AM ET
a lot of potential for the Future
1
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💎 Access the Market Tools Trusted by Thousands of Investors Get Started
1.40
-0.22
-13.55%
- Volume: 857,675
- Bid/Ask: 0.00 / 0.00
- Day's Range: 1.38 - 1.60
Mithra Pharmaceuticals Sa
1.40
-0.22
-13.55%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Index Component
Mithra Pharmaceuticals Sa Company Profile
Get an in-depth profile of Mithra Pharmaceuticals Sa, including a general overview of the company's business and key management, as well as employee data and location and contact information.
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
Contact Information
Top Executives
| Name | Age | Since | Title |
|---|---|---|---|
| Christian Homsy | 65 | 2023 | Independent Chairman |
| Inge Beernaert | - | 2023 | Independent Director |
| Jacques Galloy | 53 | 2023 | Independent Director |
| Valerie Gordenne | - | 2021 | Non-Executive Director |
| Sidney D. Bens | - | 2023 | Independent Director |
| Jean-Michel Foidart | - | 2016 | President of the Scientific Advisory Board & Executive Director |
Write your thoughts about Mithra Pharmaceuticals Sa
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Grégory Vervoort
Aug 12, 2022 4:01PM ET
Mega deal to come with catalent (CTLT) ?
0
0
Phildb
Aug 10, 2022 3:40AM ET
The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
0
0
Phildb
Aug 01, 2022 3:15AM ET
Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
2
0
Phildb
Jul 26, 2022 2:20AM ET
NEXSTELLIS® oral contraceptive now available in Australia26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia. NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent. Leon Van Rompay, CEO Mithra Women’s Health
0
0
Phildb
Jul 01, 2022 7:02AM ET
LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 54 million available to Mithra.
0
0
Global_K
May 06, 2022 5:42AM ET
1 month later and 8.16, where's the bottom?
0
0
Global_K
Apr 06, 2022 6:09AM ET
11.70, curious how low this can go. price now certainly does not represent future profits
0
0
Global_K
Mar 08, 2022 3:56AM ET
14.00? Time to accumulate for a near future
0
0
Sonic the hedgehog
Mar 26, 2021 9:39AM ET
Approval in EU is a fact. next US!
3
0
Robert Jacketti
Mar 26, 2021 9:39AM ET
Approval US is also a fact !
1
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review